Highlights & Basics
- Vascular dementia is characterized by a chronic progressive multifaceted impairment of cognitive function.
- Loss of brain parenchyma is predominantly from cerebrovascular causes such as infarction and small-vessel changes.
- Vascular dementia is the second most common cause of dementia in older people after Alzheimer disease.
- A large overlap exists between vascular and Alzheimer disease and many patients have a mixed form of dementia.
- Early aggressive treatment of vascular risk factors is suggested in order to prevent further cerebrovascular disease. Supportive care and management of behavioral and psychological symptoms are also important. Treatments aimed at improving cognitive symptoms have shown no clear benefit.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Citations
Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke - Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006 Sep;37(9):2220-41.[Abstract][Full Text]
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
American College of Radiology. ACR appropriateness criteria: dementia. 2024 [internet publication].[Full Text]
Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-467.[Full Text]
1. Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke - Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006 Sep;37(9):2220-41.[Abstract][Full Text]
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
3. American Psychiatric Association. DSM-5-TR neurocognitive disorders supplement. Updated excerpts for delirium codes major and mild neurocognitive disorders. October 2022.[Full Text]
4. World Health Organization. Dementia. Mar 2023 [internet publication].[Full Text]
5. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 Jan;18(1):88-106.[Abstract][Full Text]
6. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health. 2022 Feb;7(2):e105-25.[Abstract][Full Text]
7. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29(1-2):125-32.[Abstract]
8. Braffman BH, Zimmerman RA, Trojnowski JQ, et al. Brain MR: pathologic correlation with gross and histopathology. II. Hyperintense white matter foci in the elderly. AJR Am J Roentgenol. 1988 Sep;151(3):559-66.[Abstract][Full Text]
9. De Reuck J, Deramecourt V, Cordonnier C, et al. The incidence of post-mortem neurodegenerative and cerebrovascular pathology in mixed dementia. J Neurol Sci. 2016 Jul 15;366:164-6.[Abstract]
10. Perneczky R, Tene O, Attems J, et al. Is the time ripe for new diagnostic criteria of cognitive impairment due to cerebrovascular disease? Consensus report of the International Congress on Vascular Dementia working group. BMC Med. 2016 Nov 3;14(1):162.[Abstract][Full Text]
11. Bowler JV. Modern concept of vascular cognitive impairment. Br Med Bull. 2007;83:291-305.[Abstract]
12. Hagnell O, Franck A, Grasbeck A, et al. Vascular dementia in the Lunby study: 1. a prospective, epidemiological study of incidence and risk from 1957-1972. Neuropsychobiology. 1992;26(1-2):43-9.[Abstract]
13. Gorelick PB, Brody JA, Cohen DC, et al. Risk factors for dementia associated with multiple cerebral infarcts: a case-control analysis in predominantly African-American hospital-based patients. Arch Neurol. 1993 Jul;50(7):714-20.[Abstract]
14. Mehta KM, Yeo GW. Systematic review of dementia prevalence and incidence in United States race/ethnic populations. Alzheimers Dement. 2017 Jan;13(1):72-83.[Abstract]
15. Bothongo PLK, Jitlal M, Parry E, et al. Dementia risk in a diverse population: a single-region nested case-control study in the East End of London. Lancet Reg Health Eur. 2022 Apr;15:100321.[Abstract][Full Text]
16. Brundel M, de Bresser J, van Dillen JJ, et al. Cerebral microinfarcts: a systematic review of neuropathological studies. J Cereb Blood Flow Metab. 2012 Mar;32(3):425-36.[Abstract]
17. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019 Jul;18(7):684-96.[Abstract]
18. El Husseini N, Katzan IL, Rost NS, et al. Cognitive impairment after ischemic and hemorrhagic stroke: a scientific statement from the American Heart Association/American Stroke Association. Stroke. 2023 Jun;54(6):e272-91.[Abstract][Full Text]
19. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001 Jun 16;322(7300):1447-51.[Abstract][Full Text]
20. Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology. 1999 Dec 10;53(9):1937-42.[Abstract]
21. UK Health Security Agency. Air pollution: cognitive decline and dementia. Jul 2022 [internet publication].[Full Text]
22. Sipilä PN, Heikkilä N, Lindbohm JV, et al. Hospital-treated infectious diseases and the risk of dementia: a large, multicohort, observational study with a replication cohort. Lancet Infect Dis. 2021 Nov;21(11):1557-67.[Abstract][Full Text]
23. Vestin E, Boström G, Olsson J, et al. Herpes simplex viral infection doubles the risk of dementia in a contemporary cohort of older adults: a prospective study. J Alzheimers Dis. 2024;97(4):1841-50.[Abstract][Full Text]
24. Wallin A, Milos V, Sjogren M, et al. Classification and subtypes of vascular dementia. International Psychogeriatrics. 2003;15 Suppl 1:27-37.[Abstract]
25. Horowitz DR, Tuhrim S, Weinberger JM, et al. Mechanisms in lacunar infarction. Stroke. 1992 Mar;23(3):325-7.[Abstract]
26. Bateman GA. Pulse-wave encephalopathy: a comparative study of the hydrodynamics of leukoaraiosis and normal pressure hydrocephalus. Neuroradiology. 2002 Sep;44(9):740-8.[Abstract]
27. Lee SH, Kim SM, Kim N, et al. Cortico-subcortical distribution of microbleeds is different between hypertension and cerebral amyloid angiopathy. J Neurol Sci. 2007 Jul 15;258(1-2):111-4.[Abstract]
28. Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. J Neurol Sci. 2007 Jun 15;257(1-2):80-7.[Abstract]
29. Tatemichi TK, Desmond DW, Paik M, et al. Clinical determinants of dementia related to stroke. Ann Neurol. 1993 Jun;33(6):568-75.[Abstract]
30. White L, Petrovitch H, Ross GW, et al. Prevalence of dementia in older Japanese American men in Hawaii: the Honolulu-Asia aging study. JAMA. 1996 Sep 25;276(12):955-60.[Abstract]
31. Whitmer RA, Gunderson EP, Quesenberry CP, et al. Body mass index in midlife and risk of Alzheimer's disease and vascular dementia. Curr Alzheimer Res. 2007 Apr;4(2):103-9.[Abstract]
32. Ma Y, Ajnakina O, Steptoe A, et al. Higher risk of dementia in english older individuals who are overweight or obese. Int J Epidemiol. 2020 Aug 1;49(4):1353-65.[Abstract][Full Text]
33. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996 Apr 27;347(9009):1141-5.[Abstract]
34. Guo Z, Viitanen M, Fratiglioni L, et al. Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ. 1996 Mar 30;312(7034):805-8.[Abstract][Full Text]
35. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024 Aug 10;404(10452):572-628.
36. Gupta A, Perdomo S, Billinger S, et al. Treatment of hypertension reduces cognitive decline in older adults: a systematic review and meta-analysis. BMJ Open. 2020 Nov 17;10(11):e038971.[Abstract][Full Text]
37. Pohjasvaara T, Erkinjuntti T, Ylikoski R, et al. Clinical determinants of post stroke dementia. Stroke. 1998 Jan;29(1):75-81.[Abstract]
38. Doney ASF, Bonney W, Jefferson E, et al. Investigating the relationship between type 2 diabetes and dementia using electronic medical records in the GoDARTS bioresource. Diabetes Care. 2019 Oct;42(10):1973-80.[Abstract][Full Text]
39. Celis-Morales CA, Franzén S, Eeg-Olofsson K, et al. Type 2 diabetes, glycemic control, and their association with dementia and Its major subtypes: findings from the Swedish National Diabetes Register. Diabetes Care. 2022 Mar 1;45(3):634-41.[Abstract][Full Text]
40. Cholerton B, Baker LD, Montine TJ, et al. Type 2 diabetes, cognition, and dementia in older adults: toward a precision health approach. Diabetes Spectr. 2016 Nov;29(4):210-9.[Abstract][Full Text]
41. Moran C, Lacy ME, Whitmer RA, et al. Glycemic control over multiple decades and dementia risk in people with type 2 diabetes. JAMA Neurol. 2023 Jun 1;80(6):597-604.[Abstract][Full Text]
42. Wu CY, Iskander C, Wang C, et al. Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study. Diabetes Care. 2023 Feb 1;46(2):297-304.[Abstract][Full Text]
43. Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama study. Neurology. 1995 Jun;45(6):1161-8.[Abstract]
44. Langballe EM, Ask H, Holmen J, et al. Alcohol consumption and risk of dementia up to 27 years later in a large, population-based sample: the HUNT study, Norway. Eur J Epidemiol. 2015 Sep;30(9):1049-56.[Abstract][Full Text]
45. Xu W, Wang H, Wan Y, et al. Alcohol consumption and dementia risk: a dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2017 Jan;32(1):31-42.[Abstract]
46. Kjaergaard AD, Johannesen BR, Sørensen HT, et al. Kidney disease and risk of dementia: a Danish nationwide cohort study. BMJ Open. 2021 Oct 22;11(10):e052652.[Abstract][Full Text]
47. Peters R, Xu Y, Fitzgerald O, et al. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J. 2022 Dec 21;43(48):4980-90.[Abstract][Full Text]
48. Guo J, Liu Y, Jia J, et al. Effects of rhythm-control and rate-control strategies on cognitive function and dementia in atrial fibrillation: a systematic review and meta-analysis. Age Ageing. 2024 Feb 1;53(2):afae009.[Abstract]
49. Gottesman RF, Albert MS, Alonso A, et al. Associations between midlife vascular risk factors and 25-year incident dementia in the atherosclerosis risk in communities (ARIC) cohort. JAMA Neurol. 2017 Oct 1;74(10):1246-54.[Abstract][Full Text]
50. Song R, Xu H, Dintica CS, et al. Associations between cardiovascular risk, structural brain changes, and cognitive decline. J Am Coll Cardiol. 2020 May 26;75(20):2525-34.[Abstract][Full Text]
51. Juul Rasmussen I, Rasmussen KL, Nordestgaard BG, et al. Impact of cardiovascular risk factors and genetics on 10-year absolute risk of dementia: risk charts for targeted prevention. Eur Heart J. 2020 Nov 1;41(41):4024-33.[Abstract][Full Text]
52. Dove A, Guo J, Marseglia A, et al. Cardiometabolic multimorbidity and incident dementia: the Swedish twin registry. Eur Heart J. 2023 Feb 14;44(7):573-82.[Abstract][Full Text]
53. Juul Rasmussen I, Frikke-Schmidt R. Modifiable cardiovascular risk factors and genetics for targeted prevention of dementia. Eur Heart J. 2023 Jul 21;44(28):2526-43.[Abstract][Full Text]
54. Ben Hassen C, Fayosse A, Landré B, et al. Association between age at onset of multimorbidity and incidence of dementia: 30 year follow-up in Whitehall II prospective cohort study. BMJ. 2022 Feb 2;376:e068005.[Abstract][Full Text]
55. Gallaway PJ, Miyake H, Buchowski MS, et al. Physical activity: a viable way to reduce the risks of mild cognitive impairment, Alzheimer's disease, and vascular dementia in older adults. Brain Sci. 2017 Feb 20;7(2):22.[Abstract][Full Text]
56. Hansson O, Svensson M, Gustavsson AM, et al. Midlife physical activity is associated with lower incidence of vascular dementia but not Alzheimer's disease. Alzheimers Res Ther. 2019 Oct 20;11(1):87.[Abstract][Full Text]
57. Iso-Markku P, Aaltonen S, Kujala UM, et al. Physical activity and cognitive decline among older adults: a systematic review and meta-analysis. JAMA Netw Open. 2024 Feb 5;7(2):e2354285.[Abstract][Full Text]
58. Del Pozo Cruz B, Ahmadi M, Naismith SL, et al. Association of daily step count and intensity with incident dementia in 78 430 adults living in the UK. JAMA Neurol. 2022 Oct 1;79(10):1059-63.[Abstract][Full Text]
59. Gebhard C, Corpataux N, Gräni C, et al. Lipid-lowering therapy and the risk of dementia: lessons learned from two decades of controversy. Eur Heart J. 2023 Jun 1;44(21):1855-7.[Full Text]
60. Hussain SM, Robb C, Tonkin AM, et al. Association of plasma high-density lipoprotein cholesterol level with risk of incident dementia: a cohort study of healthy older adults. Lancet Reg Health West Pac. 2024 Feb;43:100963.[Abstract][Full Text]
61. Cantuaria ML, Pedersen ER, Waldorff FB, et al. Hearing loss, hearing aid use, and risk of dementia in older adults. JAMA Otolaryngol Head Neck Surg. 2024 Feb 1;150(2):157-64.[Abstract]
62. Parish S, Mafham M, Offer A, et al. Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. Eur Heart J. 2022 Jun 1;43(21):2010-9.[Abstract][Full Text]
63. Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. JAMA. 2019 Oct 22;322(16):1589-99.[Abstract][Full Text]
64. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May 8;56(9):1143-53.[Abstract][Full Text]
65. American College of Radiology. ACR appropriateness criteria: dementia. 2024 [internet publication].[Full Text]
66. Clarfield AM. The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med. 2003 Oct 13;163(18):2219-29.[Abstract][Full Text]
67. Hejl AM, Hogh P, Waldemar G. Potentially reversible conditions in 1000 consecutive memory clinic patients. J Neurol Neurosurg Psychiatry. 2002 Oct;73(4):390-4.[Abstract][Full Text]
68. Alothman D, Card T, Lewis S, et al. Risk of suicide after dementia diagnosis. JAMA Neurol. 2022 Oct 3;79(11):1148-54.[Abstract][Full Text]
69. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies; report of the NINDS-AIREN International Workshop. Neurology. 1993 Feb;43(2):250-60.[Abstract]
70. American College of Radiology. ACR-ACNM-ASNR-SNMMI practice parameter for brain/PET imaging in dementia. 2020 [internet publication].[Full Text]
71. Skrobot OA, O'Brien J, Black S, et al. The vascular impairment of cognition classification consensus study. Alzheimers Dement. 2017 Jun;13(6):624-33.[Abstract][Full Text]
72. Iverson DJ, Gronseth GS, Reger MA, et al. Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010 Apr 20;74(16):1316-24.[Abstract][Full Text]
73. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-467.[Full Text]
74. Williams PS, Rands G, Orrel M, et al. Aspirin for vascular dementia. Cochrane Database Syst Rev. 2000;(4):CD001296.[Abstract][Full Text]
75. Writing Committee Members, Joglar JA, Chung MK, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2024 Jan 2;83(1):109-279.[Abstract][Full Text]
76. Demaerschalk BM, Wingerchuk DM. Treatment of vascular dementia and vascular cognitive impairment. Neurologist. 2007 Jan;13(1):37-41.[Abstract]
77. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007 Sep;6(9):782-92.[Abstract]
78. Korczyn AD. Drugs for vascular dementia. Lancet Neurol. 2007 Sep;6(9):749-51.[Abstract]
79. Black SE. Therapeutic issues in vascular dementia: studies, designs and approaches. Can J Neurol Sci. 2007 Mar;34 Suppl 1:S125-30.[Abstract]
80. Wilkinson D, Róman G, Salloway S, et al. The long-term efficacy and tolerability of donepezil in patients with vascular dementia. Int J Geriatr Psychiatry. 2010 Mar;25(3):305-13.[Abstract]
81. McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;(3):CD003154.[Abstract][Full Text]
82. Battle CE, Abdul-Rahim AH, Shenkin SD, et al. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev. 2021 Feb 22;2(2):CD013306.[Abstract][Full Text]
83. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593.[Abstract][Full Text]
84. Holmes C, Cairns N, Lantos P, et al. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry. 1999 Jan;174:45-50.[Abstract]
85. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012 Mar 8;366(10):893-903.[Abstract][Full Text]
86. Truong C, Recto C, Lafont C, et al. Effect of cholinesterase inhibitors on mortality in patients with dementia: a systematic review of randomized and nonrandomized trials. Neurology. 2022 Nov 14;99(20):e2313-25.[Abstract][Full Text]
87. Hanon O, Forette F. Prevention of dementia: lessons from SYST-EUR and PROGRESS. J Neurol Sci. 2004 Nov 15;226(1-2):71-4.[Abstract]
88. López Arrieta J, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002;(3):CD000147.[Abstract][Full Text]
89. Shah K, Qureshi SU, Johnson M, et al. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother. 2009 Oct;7(5):250-61.[Abstract]
90. McGuinness B, Todd S, Passmore P, et al. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD004034.[Abstract][Full Text]
91. Zonneveld TP, Richard E, Vergouwen MD, et al. Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2018 Jul 19;(7):CD007858.[Abstract][Full Text]
92. Hughes D, Judge C, Murphy R, et al. Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. JAMA. 2020 May 19;323(19):1934-44.[Abstract][Full Text]
93. Etminan M, Gill S, Sammii A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy. 2003 Jun;23(6):726-30.[Abstract]
94. Bernick C, Katz R, Smith NL, et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology. 2005 Nov 8;65(9):1388-94.[Abstract]
95. McGuinness B, Craig D, Bullock R, et al. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016 Jan 4;(1):CD003160.[Abstract][Full Text]
96. Goldstein LB, Toth PP, Dearborn-Tomazos JL, et al. Aggressive LDL-C lowering and the brain: impact on risk for dementia and hemorrhagic stroke: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2023 Oct;43(10):e404-42.[Abstract][Full Text]
97. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016 Nov 19;388(10059):2532-61.[Abstract][Full Text]
98. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019 Jun 18;139(25):e1082-143.[Abstract][Full Text]
99. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405-12.[Abstract][Full Text]
100. Carrion C, Folkvord F, Anastasiadou D, et al. Cognitive therapy for dementia patients: a systematic review. Dement Geriatr Cogn Disord. 2018;46(1-2):1-26.[Abstract][Full Text]
101. Bahar-Fuchs A, Martyr A, Goh AM, et al. Cognitive training for people with mild to moderate dementia. Cochrane Database Syst Rev. 2019 Mar 25;(3):CD013069.[Abstract][Full Text]
102. Woods B, Aguirre E, Spector AE, et al. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD005562.[Abstract][Full Text]
103. Kudlicka A, Martyr A, Bahar-Fuchs A, et al. Cognitive rehabilitation for people with mild to moderate dementia. Cochrane Database Syst Rev. 2023 Jun 29;6(6):CD013388.[Abstract][Full Text]
104. Leng M, Zhao Y, Wang Z. Comparative efficacy of non-pharmacological interventions on agitation in people with dementia: A systematic review and Bayesian network meta-analysis. Int J Nurs Stud. 2020 Feb;102:103489.[Abstract]
105. Möhler R, Renom A, Renom H, et al. Personally tailored activities for improving psychosocial outcomes for people with dementia in community settings. Cochrane Database Syst Rev. 2020 Aug 17;(8):CD010515.[Abstract][Full Text]
106. Orgeta V, Qazi A, Spector A, et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment: systematic review and meta-analysis. Br J Psychiatry. 2015 Oct;207(4):293-8.[Abstract][Full Text]
107. Bell G, Baou CE, Saunders R, et al. Effectiveness of primary care psychological therapy services for the treatment of depression and anxiety in people living with dementia: evidence from national healthcare records in England. EClinicalMedicine. 2022 Oct;52:101692.[Abstract][Full Text]
108. Watt JA, Goodarzi Z, Veroniki AA, et al. Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis. BMJ. 2021 Mar 24;372:n532.[Abstract][Full Text]
109. Gottesman RF, Lutsey PL, Benveniste H, et al. Impact of sleep disorders and disturbed sleep on brain health: a scientific statement from the American Heart Association. Stroke. 2024 Mar;55(3):e61-76.[Abstract][Full Text]
110. Wilfling D, Calo S, Dichter MN, et al. Non-pharmacological interventions for sleep disturbances in people with dementia. Cochrane Database Syst Rev. 2023 Jan 3;1(1):CD011881.[Abstract][Full Text]
111. Park JH, Lee SB, Lee JJ, et al. Depression in vascular dementia is quantitively and qualitatively different from depression in Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;23:67-73.[Abstract]
112. Dudas R, Malouf R, McCleery J, et al. Antidepressants for treating depression in dementia. Cochrane Database Syst Rev. 2018 Aug 31;(8):CD003944.[Abstract][Full Text]
113. Rabins PV, Rovner BW, Rummans T, et al. Guideline watch (October 2014): practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Focus (Am Psychiatr Publ). 2017 Jan;15(1):110-28.[Abstract][Full Text]
114. Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008191.[Abstract][Full Text]
115. Zivkovic S, Koh CH, Kaza N, et al. Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis. BMC Psychiatry. 2019 Jun 20;19(1):189.[Abstract][Full Text]
116. Huang KL, Fang CJ, Hsu CC, et al. Myocardial infarction risk and antipsychotics use revisited: a meta-analysis of 10 observational studies. J Psychopharmacol. 2017 Dec;31(12):1544-55.[Abstract]
117. Schneider-Thoma J, Efthimiou O, Huhn M, et al. Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiatry. 2018 Aug;5(8):653-63.[Abstract]
118. Kheirbek RE, Fokar A, Little JT, et al. Association between antipsychotics and all-cause mortality among community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2019 Nov 13;74(12):1916-21.[Abstract][Full Text]
119. Chien LY, Chu H, Guo JL, et al. Caregiver support groups in patients with dementia: a meta-analysis. Int J Geriatr Psychiatry. 2011 Oct;26(10):1089-98.[Abstract]
120. Graff MJ, Adang EM, Vernooij-Dassen MJ, et al. Community occupational therapy for older patients with dementia and their care givers: cost effectiveness study. BMJ. 2008 Jan 19;336(7636):134-8.[Abstract][Full Text]
121. American Academy of Neurology. Assessing patients in a neurology practice for risk of falls. Feb 2008 [internet publication].[Full Text]
122. Chiong W, Tsou AY, Simmons Z, et al. Ethical considerations in dementia diagnosis and care: AAN position statement. Neurology. 2021 Jul 13;97(2):80-9.[Abstract][Full Text]
123. Taylor LP, Besbris JM, Graf WD, et al. Clinical guidance in neuropalliative care: an AAN position statement. Neurology. 2022 Mar 8;98(10):409-16.[Abstract][Full Text]
124. Davies N, Barrado-Martín Y, Vickerstaff V, et al. Enteral tube feeding for people with severe dementia. Cochrane Database Syst Rev. 2021 Aug 13;(8):CD013503.[Abstract][Full Text]
125. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al; The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. 2006 Aug 10;355(6):549-59.[Abstract][Full Text]
126. Gotoh F, Tohgi H, Hirai S, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2000 Jul-Aug;9(4):147-57.[Abstract]
127. Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010 Oct;9(10):959-68.[Abstract]
128. World Health Organization. Risk reduction of cognitive decline and dementia. 2019 [internet publication].[Full Text]
129. Liang CS, Li DJ, Yang FC, et al. Mortality rates in alzheimer's disease and non-alzheimer's dementias: a systematic review and meta-analysis. Lancet Healthy Longev. 2021 Aug;2(8):e479-88.[Abstract][Full Text]
130. O'Brien J. Behavioral symptoms in vascular cognitive impairment and vascular dementia. Int Psychogeriatr. 2003;15(suppl 1):133-138.[Abstract]
131. Ganesh A, Fraser JF, Gordon Perue GL, et al. Endovascular treatment and thrombolysis for acute ischemic stroke in patients with premorbid disability or dementia: a scientific statement from the American Heart Association/American Stroke Association. Stroke. 2022 May;53(5):e204-17.[Abstract][Full Text]
132. Wang Q, Davis PB, Gurney ME, et al. COVID-19 and dementia: analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement. 2021 Aug;17(8):1297-306.[Abstract][Full Text]
133. Vachon M, Veilleux MC, Macoir J. Promoting the maintenance of satisfactory communication: strategies used by caregivers and medical staff with people suffering from Alzheimer's disease. Geriatr Psychol Neuropsychiatr Vieil. 2017 Jun 1;15(2):185-95.[Abstract]
